A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

INTRODUCTION: Exenatide once weekly (ExeOW, Bydureon(®), Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis. METHODS: Data concerning treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Stefano, Mannucci, Edoardo, Ceriello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565650/
https://www.ncbi.nlm.nih.gov/pubmed/28674957
http://dx.doi.org/10.1007/s12325-017-0499-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565650/
https://www.ncbi.nlm.nih.gov/pubmed/28674957
http://dx.doi.org/10.1007/s12325-017-0499-6

Ejemplares similares